Summary:
Using the Mexican approach to conduct nonablative stem cell transplantation (NST), we have prospectively performed 58 allografts in individuals with various malignant and nonmalignant hematological diseases using sibling donors, either HLA identical (6/6) or compatible, with one mismatch (5/6). When comparing allografts obtained from HLA identical (n=40) or compatible (n=18) siblings, respectively, the overall median survival was found to be 33 vs 8 months (P<0.01), the 52-month survival was 47 vs 38% (P>0.2), the prevalence of acute graft-versus-host disease (GVHD) 57 vs 38%, that of chronic GVHD 25 vs 11% and the relapse rate 45 vs 55%. The two patients who failed to engraft were both 5/6 matches. Probably stemming from the low number of patients, and despite a trend toward worse results in patients allografted from HLA compatible (5/6) siblings, most differences in outcome were not significant. It seems that NST can be offered to individuals with either an HLA identical or a compatible sibling donor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Butturini A, Gale RP . Allogeneic bone marrow transplantation for leukemia. Curr Opin Hematol 1994; 1: 402–405.
Tsimberidou AM, Stavroyianni N, Viniou N, The Hellenic Cooperative Group et al. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 2003; 97: 1721–1731.
Georges G, Storb R . Review of ‘minitransplantation’: nonmyeloablative allogeneic hematopoietic stem cell transplantation. Int J Hematol 2003; 77: 3–14.
Djulbegovic B, Seidenfeld J, Bonnell C, Kumar A . Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review. Cancer Control 2003; 10: 17–31.
Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998; 91: 756–763.
Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeoablative therapy. Blood 1997; 89: 4531–4536.
Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A et al. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001; 66: 241–244.
Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A et al. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transplant 2000; 25: 131–133.
Ruiz-Argüelles GJ . Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: results of the Mexican approach. Int J Hematol 2002; 76U (Suppl 1): 376–379.
Ruiz-Argüelles GJ . Non-myeloablative bone marrow transplantation. Arch Med Res 2003; 34: 554–557.
Gómez-Almaguer D . The simplification of the SCT procedures in developing countries has resulted in cost-lowering and availability to more patients. Int J Hematol 2002; 76 (Suppl 1): 380–382.
Barr RD . The importance of lowering the costs of stem cell transplantation in developing countries. Int J Hematol 2002; 76 U (Suppl 1): 365–367.
Ruiz-Argüelles GJ, López-Martínez B, Gómez-Rangel D et al. Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience. Hematology 2003; 8: 151–154.
Ruiz-Argüelles GJ, Gómez-Rangel JD, Ponce-de-León S et al. The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease. Am J Hematol 2004; 75: 200–204.
Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B et al. No cytomegalovirus-related deaths after non-ablative stem cell allografts. Hematology 2002; 7: 95–99.
Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B et al. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002; 87: 894–896.
Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez Rancel JD et al. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute leukemia eligible for conventional allografting: a prospective study. Leukemia Lymphoma 2004; 45: 1191–1195.
Kessinger A, Armitage JO, Landmark JD et al. Autologous peripheral hematopoietic stem cell transplantation restores hemopoietic function following marrow ablative therapy. Blood 1998; 71: 723–727.
Ruiz-Argüelles A . Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin 1992; 50: 735–743.
Ruiz-Argüelles A, Orfao A . Caracterización y evaluación de células totipotenciales en sangre periférica y médula ósea. In: Ruiz-Argüelles GJ, San-Miguel JF (eds). Actualización en Leucemias. Editorial Médica Panamericana: México City, 1996 pp 79–82.
Pinkel D, Straume T, Gray JW . Cytogenetic analysis using quantitative, high sensitivity fluorescence hybridization. Proc Natl Acad Sci USA 1996; 83: 2934–2938.
Ruiz-Argüelles GJ, López-Martínez B, Santellán-Olea MR et al. Follow up of hemopoietic chimerism in individuals given allogeneic hemopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen: a prospective study in a single institution. Leukemia Lymphoma 2002; 43: 1509–1511.
Yam P, Petz L, Knowlton R et al. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation 1987; 43: 399–407.
Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V et al. Assessment of residual disease in acute leukemia by means of polymerase chain reaction: a prospective study in a single institution. Rev Invest Clin Mex 2000; 52: 118–124.
Champlin R . Nonmyeloablative chemotherapy with allogeneic hematopoietic transplantation as adoptive immunotherapy for malignancies. In: Schechter GP, Hoffman R, Schrier SL (eds). Hematology. The American Society of Hematology Education Program Book: Washington, USA, 1999, pp 413–416.
Or R, Shapira MY, Resnick I et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 441–445.
Martino R, Caballero MD, Simon JA et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100: 2243–2245.
Burnett AK, Wheatley K, Goldstone AH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385–400.
Greinix HT, Nachbaur D, Krieger O et al. Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Haematol 2002; 117: 914–923.
Feinstein Lyle C, Sandmaier BM, Hegenbart U et al. Non-myeloablative allografting from human leukocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol 2003; 1209: 281–288.
Sayer HG, Kroger M, Beyer J et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell trasplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003; 12: 1089–1095.
Anasetti C, Beatty PG, Stirb R et al. Effect of HLA incompatibility on graft versus host disease, relapse and survival after marrow transplantation in patients with leukemia and lymphoma. Hum Immunol 1990; 29: 79–91.
Ottinger H, Beelen D, Sayer H et al. Bone marrow transplantation from partially HLA matched related donors in adults with leukemia: The experience at the University Hospital of Essen, Germany. Br J Haematol 1996; 92: 913–921.
Bacigalupo A, Hows J, Gordon-Smith EC et al. Bone marrow transplantation for severe apalstic anemia from donors other tha HLA identical siblings: a report from the BMT Working Party. Bone Marrow Transplant 1988; 3: 531–535.
Powles RL, Morgenterns GR, Kay HE et al. Mismatched family donors for bone marrow transplantation as treatment for acute leukemia. Lancet 1983; 1: 612–625.
Hasegawa W, Lipton JH, Messner HA et al. Influence of one human leukocyte antigen mismatch on outcome of allogeneic bone marrow transplantation from related donors. Hematology 2003; 8: 27–33.
Ruiz-Argüelles GJ, Gómez-Almaguer D . Braking dogmata to help patients: non-myeloablative hematopoietic stem cell transplantation. Expert Opin Biol Ther 2004; 4: 1693–1699.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ruiz-Argüelles, G., López-Martínez, B., Manzano, C. et al. Significance of one human leukocyte antigen mismatch on outcome of nonmyeloablative allogeneic stem cell transplantation from related donors using the Mexican schedule. Bone Marrow Transplant 35, 335–339 (2005). https://doi.org/10.1038/sj.bmt.1704780
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704780